Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Updated Results from the Phase 1/2 Study Champion-1 (NCT01677858)
James R. Berenson(Oncotherapeutics (United States)), Jesús G. Berdeja(Tennessee Oncology), Roger M. Lyons(Hematology Oncology Associates), Janet L. Anderl(Amgen (United States)), Robert M. Rifkin(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Richy Agajanian(Oncology Institute of Hope and Innovation), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Morton Coleman(Cornell University), Robert A. Moss(Valley Regional Hospital), Wael A. Harb, Ying Ou(Hunan Normal University), Sandra Dixon(Amgen (United States)), Marco Schupp(Amgen (Switzerland)), Ralph V. Boccia(Center for Cancer and Blood Disorders), Alan Cartmell(Newcastle University)
Cited by 4
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k